iiinova — where your digital self keeps evolving

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 21/09/2026

The European Commission granted marketing authorization for our investigational therapy in primary hypercholesterolemia, both HeFH and non-familial or mixed dyslipidemia, marking an important milestone for patients affected by lipid-related conditions. Learn more: bit.ly/4iF9eAT

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 02/09/2026

The future of cardiovascular care requires continued innovation and a relentless focus on unmet need. We're participating in the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference and look forward to engaging with investors and industry leaders. Learn more: bit.ly/4x6VQsG

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 28/08/2026

We are honored to receive the 2026 Green Chemistry Challenge Award from the American Chemical Society alongside our collaborators Snapdragon Chemistry. This recognition reflects our work to rethink how medicines can be made, with strong scientific rigor and attention to sustainability.

020

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 26/08/2026

At ESC Congress 2026, we look forward to connecting with the global heart health community to discuss advances in scientific innovation and opportunities to improve outcomes for people living with cardiovascular disease and other lipid-related conditions. Learn more: bit.ly/4xpWdQ6

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 05/08/2026

What comes next in medicine is shaped by the progress we’re making today. During our Investor Day, we shared updates on our corporate, clinical and commercial progress toward potentially delivering new treatment options for patients: ir.newamsterdampharma.com/news-release...

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 29/07/2026

We know that innovation happens when scientific insight, conviction and execution come together to address patient needs. This is why we look forward to sharing key highlights about our progress during our Investor Day on August 5. Learn more and register for the webcast: bit.ly/4wwhDL1

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 24/07/2026

CHMP has issued a positive opinion – recommending marketing authorization for our investigational therapy in primary hypercholesterolemia or mixed dyslipidemia, a step forward for people living with cardiovascular disease and other lipid-related conditions. Learn more: bit.ly/3TBDamK

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 01/07/2026

Alzheimer’s research continues to evolve as we learn more about factors tied to disease risk and prevention. At AAIC 2026, we’ll share research exploring the link between heart and brain health and potential upstream approaches to Alzheimer’s prevention. Learn more: bit.ly/4vaxsp9

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 10/06/2026

Cardiovascular risk doesn’t look the same for every patient, and the approach to managing it shouldn’t either. We’re sharing data at #NLASessions 2026 to advance how lipid management and cardiovascular risk are being understood and addressed. Learn more: ir.newamsterdampharma.com/news-release...

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 08/06/2026

Advancing cardiovascular care means continuing to address the needs of patients who remain at risk despite existing treatment options. Addressing this unmet need is an opportunity we’re committed to — and one we’re excited to discuss at the Goldman Sachs 47th Annual Global Healthcare Conference.

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 12/05/2026

We are participating in two investor conferences this May: The Bank of America Securities 2026 Health Care Conference on May 12 and the 2026 RBC Capital Market’s Global Healthcare Conference on May 20. For more details on our presence and live webcast, read the full press release: bit.ly/42qqn82

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 21/04/2026

Even with LDL‑C at goal, residual cardiovascular risk may remain for people living with ASCVD due to other contributing risk factors, making comprehensive risk reduction and ongoing care essential. Learn more about LDL-C and cardiovascular risk in ASCVD: www.expectmoreforldl.com/ascvd-risk/

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 28/03/2026

We’re excited to join the cardiovascular community at the @American College of Cardiology Annual Scientific Sessions. Stop by our booth (1209) to connect with us and learn more about cardiometabolic-related residual risk and other lipid-related conditions. Hope to see you there. #ACC26

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 23/03/2026

We’re presenting new data at #ACC26 from our Phase 3 clinical trials and additional findings for cardiovascular disease and other lipid-related conditions. Learn more: www.globenewswire.com/news-release...

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 18/03/2026

Cholesterol metabolism supports brain function and is increasingly being studied for its role in Alzheimer’s disease, especially in people who carry the APOE4 gene. Our #sponsored Nature article explores how these pathways may enable earlier, prevention-focused intervention. bit.ly/3PICdHg

001

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 02/03/2026

Our leadership team will be at several conferences in March to discuss how we’re working to advance innovative therapies for cardiovascular disease (CVD) and other lipid-related conditions. Learn more about how to watch the presentations live or view the archived replays afterward: bit.ly/4slb5ML

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 02/03/2026

🔓NEW in @natmed.nature.com: Review the data from our BROOKLYN Phase 3 clinical trial, which evaluated our investigational CETP inhibitor in patients with heterozygous familial hypercholesterolemia on top of maximum tolerated lipid-lowering therapies. www.newamsterdampharma.com/wp-content/u...

020

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 27/02/2026

We’re on a mission to change the landscape of lipid-lowering treatment. By advancing innovative therapies for CVD and other lipid-related conditions, we aim to empower people to better manage their health and reduce the likelihood of serious complications. www.newamsterdampharma.com

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 16/02/2026

Alzheimer’s and Dementia Care Education Week is a timely reminder that understanding and managing lipids may support long-term brain health and overall well-being. Learn more about the connection between lipids and Alzheimer’s disease: www.newamsterdampharma.com/lipid-relate...

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 06/02/2026

As estrogen declines during menopause, cardiovascular risk rises. On Wear Red Day, learn how routine monitoring and LDL-C lowering strategies can support better long-term outcomes. Learn more: www.newamsterdampharma.com/our-focus/

Menopausal women are 18% more likely to be classified as high risk
for ASCVD than premenopausal women

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 03/02/2026

Atherosclerosis develops quietly, long before symptoms appear. Listen as Prof. Kausik Ray explains why caring for your blood vessels today can prevent urgent problems tomorrow. Learn more about cardiovascular risk factors: bit.ly/4t6kZmu

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 27/01/2026

Research suggests that sustaining lower LDL-C over time may delay ASCVD events by decades. The impact of long-term prevention can be profound, and the opportunity to improve outcomes is clear. www.expectmoreforldl.com/ldl-c-goals-...

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 21/01/2026

Drs. Alan Brown and Michael Davidson explain why addressing LDL-C from an early age can have a profound impact on long-term cardiovascular health. Learn more about LDL-C goals, guidelines, and treatment strategies: www.expectmoreforldl.com/ldl-c-goals-...

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 09/01/2026

We showcased our Phase 3 CETP inhibitor data at multiple major conferences and published findings in top-tier journals throughout 2025. With strong momentum, 2026 is shaping up to be another landmark year. Explore our strategic priorities for the year ahead: ir.newamsterdampharma.com/news-release...

Dr. Michael Davidson, CEO of NewAmsterdam Pharma, appears with a quote: "We remain committed to advancing our broader clinical development strategy, which includes three Phase 3 trials, PREVAIL, REMBRANDT, and RUBENS. In addition and based on the positive data from our Alzheimer’s disease (“AD’”) biomarker analysis from the BROADWAY trial, we are planning to start our first dedicated Alzheimer’s trial in 2026."

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 06/01/2026

Low rates of Lp(a) testing mean many patients miss opportunities to address residual cardiovascular risk. A JAHA study found that testing for Lp(a) is linked to greater initiation of lipid-lowering therapy. Learn more about residual risk factors: www.expectmoreforldl.com/ldl-c-and-be...

Only 0.4% of ASCVD patients have had a lipoprotein(a) test.
Journal of the American Heart Association

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 01/01/2026

Happy New Year from all of us at NewAmsterdam Pharma! We’re excited for what 2026 has in store, particularly as we continue to advance PREVAIL, our Phase 3 cardiovascular outcomes trial. The stage is set for another year of progress!

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 17/12/2025

Happy holidays and best wishes for a healthy and joyful New Year from all of us at NewAmsterdam Pharma! As we look ahead to 2026, we remain committed to advancing our lead investigational asset and exploring new ways to address the global impact of cardiovascular disease.

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 10/12/2025

Cholesterol isn’t just important for heart health—it’s also vital for the brain. ApoE-bound lipoproteins move cholesterol to the cells that depend on it—making it central to understanding the connection between cholesterol and Alzheimer’s disease. www.newamsterdampharma.com/lipid-relate...

Elevated cholesterol levels have been linked to an increased risk of Alzheimer’s disease later in life

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 02/12/2025

Taking charge of your heart health is a team effort. Clinical recommendations guide treatment, but your actions make the difference. Learn more about preventing heart disease from @americanheart.bsky.social: www.heart.org/en/healthy-l...

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 24/11/2025

Lp(a) isn’t as well-known as LDL-C, but high levels can sharply increase the risk of heart attacks and strokes—even in people with normal LDL. This recent @washingtonpost.com article explores Lp(a), its genetic roots, and why it’s gaining attention. wapo.st/48vKTaV

There’s Another Risk to Your Heart That’s Gaining New Attention

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 18/11/2025

A recent study found only ~40% of ASCVD patients achieved guideline-recommended LDL-C targets, highlighting the need for frequent follow-up, patient counseling, and combination therapies. Learn more about the unmet need in cardiovascular disease: www.newamsterdampharma.com/unmet-need-c...

Study finds only ~40% of patients with ASCVD met their LDL-C goals

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 14/11/2025

About 1 in 9 adults worldwide are living with diabetes, and the diagnosis doubles the risk for heart disease. People with type 2 diabetes have a similar risk of CVD as those who already have it. This #WorldDiabetesDay, learn more about our research: www.newamsterdampharma.com/lipid-relate...

Approximately 590 million adults worldwide are living with diabetes
#WorldDiabetesDay

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 13/11/2025

Lowering LDL-C is essential for cardiovascular risk reduction, but it’s not enough on its own. Our CEO Dr. Michael Davidson details why the future of hyperlipidemia management needs to go beyond LDL-C. bit.ly/3LAQSCA

Looking Beyond LDL-C: Broadening the Approach to Reducing Cardiovascular Risk - an article by Dr. Michael Davidson, CEO, NewAmsterdam Pharma

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 10/11/2025

Happening now at #AHA25: José Inia leads a digital poster presentation on a preclinical analysis evaluating a combination approach to targeting atherosclerotic plaque lesions. Review the abstract to learn more about our investigational CETP inhibitor: eppro02.ativ.me//web/index.p...

Obicetrapib in combination with ezetimibe on top of atorvastatin regresses atherosclerotic plaque lesions in APOE*3-Leiden.CETP mice

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 09/11/2025

LDL-C isn’t the whole picture. Other factors like LDL particles, ApoB, Lp(a), non-HDL-C, and low HDL-C can contribute to residual ASCVD risk. Learn about each of these factors: www.expectmoreforldl.com/ldl-c-and-be...

Uncovering residual risk means assessing LDL-C--and more contributing factors.

011

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 08/11/2025

ASCVD risk reduction begins with lowering LDL-C, but residual cardiovascular risk remains and contributes to 400,000 deaths in the US each year. To change that trajectory, we’re challenging ourselves to expect more from lipid-lowering therapies. www.expectmoreforldl.com?utm_source=s...

ASCVD affects ~26 million US adults and results in 400,000 deaths annually. Source: National Library of Medicine

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 07/11/2025

New this weekend at #AHA25: Don’t miss our CSO Dr. John Kastelein’s oral presentation on an analysis of pooled LDL particle data from our Phase 3 program evaluating our investigational CETP inhibitor. Make sure this session is part of your conference plan: eppro02.ativ.me/appinfo.php?...

Cholesteryl Ester Transfer Protein (CETP) Inhibition and LDL Particles: Pooled Analysis of BROOKLYN and BROADWAY Phase 3 Clinical Trials

001

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 05/11/2025

We closed the third quarter with continued momentum—advancing our clinical programs, sharing new scientific insights, and preparing for what’s ahead. Read our latest corporate update and Q3 2025 financial results: ir.newamsterdampharma.com/news-release...

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 28/10/2025

Even when taking statins, many ASCVD patients face residual cardiovascular risk.

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 27/10/2025

LDL-C is only part of the story. Research published in Frontiers suggests that LDL particle number (LDL-P) is a more accurate predictor of cardiovascular risk than LDL-C. Read the article: www.frontiersin.org/journals/phy...

Addressing factors beyond LDL-C is essential to maximize cardiovascular
risk reduction

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 20/10/2025

We’re excited to see our Alzheimer’s disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in the Journal of Prevention of Alzheimer’s Disease. 🔓 Read the open access article: www.newamsterdampharma.com/wp-content/u...

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 15/10/2025

Combination lipid-lowering therapy could prevent 330K deaths globally every year, according to a recent meta-analysis. The findings, drawn from data on over 108,000 patients, make a case to rethink the standard treatment approach. Read more: www.mayoclinicproceedings.org/pb-assets/He...

Combination lipid-lowering therapy could prevent 330,000 per year globally, including deaths 50,000 in the U.S.

000

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 02/10/2025

Despite gradual improvements from 2014 to 2023, too many people with ASCVD are falling short of guideline-recommended lipid levels or not receiving treatment. We’re working to close this gap by advancing therapies with the potential to help more people reach their goals. bit.ly/476bTgz

66% of individuals with ASCVD failed to attain an LDL-C level <70 mg/dL

45% received no LDL-C lowering therapy

020

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 30/09/2025

Despite being on lipid-lowering therapies, many patients still have LDL-C levels above recommended targets. This LDL-C Awareness Day, take a moment for your health—talk to your doctor and see if it's time for a cholesterol check.

020

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 29/09/2025

This World Heart Day, we’re joining the global call to reduce the burden of cardiovascular disease, the world’s leading cause of death. Our mission: advance research in pursuit of a future where heart disease is no longer the #1 killer. Learn more at bit.ly/3VCUu8V

020

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 25/09/2025

A new analysis in @jme-journal.bsky.social identifies a costly gap in heart health. A majority of Americans with hypercholesterolemia are on statins, but most don't hit their LDL-C targets. Getting to goal was associated with a 50% reduction in cardiovascular events. bit.ly/48xvWWf

New research in the Journal of Medical Economics: Assessment of unmet clinical needs and healthcare resource use among statin-treated patients with or at risk of developing atherosclerotic cardiovascular disease

021

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 24/09/2025

>7M Americans live with Alzheimer’s, and that number could reach 13M by 2050. Cholesterol plays a critical role in brain health, and research suggests there could be a link between lipid metabolism in the brain and Alzheimer’s. Take a closer look at the science: bit.ly/3KhaOty

World Alzheimer's Month - Ask about Alzheimer's

010

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 22/09/2025

Nimble, agile, and locked in with our patient focus. Our Chief Commercial Officer BJ Jones shares some of what makes our culture unique, from having a still-practicing clinician as CEO, to the clarity of our shared mission. Learn more about us: www.newamsterdampharma.com/aboutus?utm_...

020

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 17/09/2025

We’re excited to join the patients, clinicians, and researchers gathering for #FHFSummit25 with the goal of “Catalyzing Collective Action for Lp(a) & FH.” As sponsors, we look forward to being part of conversations that lead to meaningful change. familyheart.org/2025-family-...

Family Heart Global Summit, September 20-21, Atlanta, GA

030

NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 08/09/2025

Addressing cholesterol dysregulation in the brain may help delay the formation of amyloid plaque and tau tangle buildup that contributes to Alzheimer’s disease. Explore the science: bit.ly/42naX4D

010